TVTX Travere Therapeutics, Inc.

NASDAQ
$51.10

Travere Therapeutics, Inc. (TVTX) Earnings News

Earnings press releases, previews and reviews for Travere Therapeutics, Inc. (TVTX), newest first. Our most recent is review: Travere's FILSPARI Tops $200 Million as Revenue Beats, but a Deal Charge Drives an EPS Miss and Softer New-Patient Starts Cloud the Ramp.